Global Neurological Drugs Market Growth 2024-2030
The global neurological drugs market is rapidly growing, driven by the increasing prevalence of neurological disorders and the development of advanced treatments.
- Bonafide Trust
- 21-08-2024
- Pages : 154
- Figures : 79
- Tables : 177
- Region : Global
- Category : Lifescience & Healthcare
- Pharmaceutical
The global neurological drugs market is a rapidly growing segment of the pharmaceutical industry. Neurological drugs are used to treat a variety of conditions affecting the brain and nervous system, including Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis. These drugs help manage symptoms, slow disease progression, and improve the quality of life for patients. The market is driven by factors such as the increasing prevalence of neurological disorders, advancements in medical research, and the rising demand for more effective treatment options. Innovations in biotechnology and pharmaceuticals, such as gene therapy, stem cell therapy, and precision medicine, are leading to the development of novel therapies that target specific neurological pathways and mechanisms. Additionally, improved diagnostic tools and techniques are enabling earlier and more accurate detection of neurological conditions, further driving the demand for neurological drugs. Public health initiatives and campaigns aimed at raising awareness about neurological disorders are also encouraging people to seek medical help, boosting the market for these drugs. The global neurological drugs market is expected to continue its growth trajectory, driven by ongoing advancements in medical research and technology, as well as the increasing need for effective treatments for neurological conditions. Nervous system diseases are diseases that occur in the central nervous system, peripheral nervous system, and autonomic nervous system, mainly manifested in sensory, motor, consciousness, and autonomic dysfunction.
The global Neurological Drugs market size is projected to grow from US$ 115430 million in 2023 to US$ 193720 million in 2030; it is expected to grow at a CAGR of 7.7% from 2024 to 2030.
The global neurological drugs market is driven by several key factors, including the increasing prevalence of neurological disorders, advancements in medical research, rising healthcare expenditures, and government initiatives. Neurological disorders, such as Alzheimer's disease, Parkinson's disease, epilepsy, and multiple sclerosis, are becoming more common due to the aging global population and greater exposure to environmental, metabolic, and lifestyle risk factors. This rising prevalence is driving the demand for effective treatments and medications. Advancements in medical research, including the development of gene therapy, stem cell therapy, and precision medicine, are leading to the creation of novel therapies that target specific neurological pathways and mechanisms. Additionally, increasing healthcare expenditures and government initiatives aimed at improving healthcare infrastructure and access to treatments are further propelling market growth. These factors collectively contribute to the expansion of the global neurological drugs market, ensuring the availability of advanced treatment options for patients with neurological conditions. This Insight Report provides a comprehensive analysis of the global Neurological Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neurological Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neurological Drugs market.
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleThe global neurological drugs market is segmented by type into anticonvulsants, CNS stimulants, antidepressants, antipsychotics, and others. Anticonvulsants are used to treat seizure disorders such as epilepsy by reducing the frequency and severity of seizures. CNS stimulants enhance brain activity and are commonly prescribed for conditions like ADHD and narcolepsy. Antidepressants are employed to manage depression and other mood disorders by balancing neurotransmitters in the brain. Antipsychotics are used to treat schizophrenia and other psychotic disorders by controlling symptoms such as hallucinations and delusions. The "others" category includes various drugs used for different neurological conditions, such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Each type of neurological drug plays a crucial role in managing symptoms, slowing disease progression, and improving the quality of life for patients. Continuous advancements in pharmaceutical research and development are leading to the creation of more effective and targeted therapies, driving the growth of the global neurological drugs market.
The global neurological drugs market is segmented by application into hospitals, specialty clinics, homecare, and others. Hospitals are the primary setting for the administration of neurological drugs, where patients receive acute care and treatment for severe neurological conditions. Specialty clinics focus on the diagnosis and management of specific neurological disorders, offering specialized care and access to advanced therapies. Homecare involves the administration of neurological drugs in a patient's home, providing convenience and continuity of care for chronic conditions. The "others" category includes various settings, such as rehabilitation centers and long-term care facilities, where neurological drugs are used to manage symptoms and improve patient outcomes. Each application segment plays a crucial role in ensuring the effective delivery of neurological drugs, supporting the overall growth of the global market. Continuous advancements in healthcare infrastructure and patient care practices are essential for meeting the evolving needs of patients with neurological disorders.
The regional analysis of the global neurological drugs market reveals distinct trends and growth patterns across different geographical areas, highlighting its critical role in supporting regional economic development. The North American region holds a dominant position, driven by a high prevalence of neurological disorders, advanced healthcare infrastructure, and the presence of key market players. The European region follows closely, with stringent regulatory frameworks and a strong focus on healthcare innovation. The Asia-Pacific region, particularly China and India, is experiencing rapid growth due to increasing healthcare expenditures, rising awareness of neurological conditions, and supportive government policies. The Latin American region and the Middle East and Africa regions are emerging markets, with growing investments in healthcare infrastructure and increasing demand for neurological drugs. Each region presents unique opportunities and challenges, with regional players adapting to local market conditions and regulatory environments to drive growth and innovation in the global neurological drugs market.
Table of Contents
- 1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
- 2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Neurological Drugs Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Neurological Drugs by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Neurological Drugs by Country/Region, 2019, 2023 & 2030
- 2.2 Neurological Drugs Segment by Type
- 2.2.1 Non-prescription drugs
- 2.2.2 Prescription
- 2.3 Neurological Drugs Sales by Type
- 2.3.1 Global Neurological Drugs Sales Market Share by Type (2019-2024)
- 2.3.2 Global Neurological Drugs Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Neurological Drugs Sale Price by Type (2019-2024)
- 2.4 Neurological Drugs Segment by Application
- 2.4.1 Hospital
- 2.4.2 Clinic
- 2.5 Neurological Drugs Sales by Application
- 2.5.1 Global Neurological Drugs Sale Market Share by Application (2019-2024)
- 2.5.2 Global Neurological Drugs Revenue and Market Share by Application (2019-2024)
- 2.5.3 Global Neurological Drugs Sale Price by Application (2019-2024)
- 3 Global Neurological Drugs by Company
- 3.1 Global Neurological Drugs Breakdown Data by Company
- 3.1.1 Global Neurological Drugs Annual Sales by Company (2019-2024)
- 3.1.2 Global Neurological Drugs Sales Market Share by Company (2019-2024)
- 3.2 Global Neurological Drugs Annual Revenue by Company (2019-2024)
- 3.2.1 Global Neurological Drugs Revenue by Company (2019-2024)
- 3.2.2 Global Neurological Drugs Revenue Market Share by Company (2019-2024)
- 3.3 Global Neurological Drugs Sale Price by Company
- 3.4 Key Manufacturers Neurological Drugs Producing Area Distribution, Sales Area, Product Type
- 3.4.1 Key Manufacturers Neurological Drugs Product Location Distribution
- 3.4.2 Players Neurological Drugs Products Offered
- 3.5 Market Concentration Rate Analysis
- 3.5.1 Competition Landscape Analysis
- 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion
- 4 World Historic Review for Neurological Drugs by Geographic Region
- 4.1 World Historic Neurological Drugs Market Size by Geographic Region (2019-2024)
- 4.1.1 Global Neurological Drugs Annual Sales by Geographic Region (2019-2024)
- 4.1.2 Global Neurological Drugs Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Neurological Drugs Market Size by Country/Region (2019-2024)
- 4.2.1 Global Neurological Drugs Annual Sales by Country/Region (2019-2024)
- 4.2.2 Global Neurological Drugs Annual Revenue by Country/Region (2019-2024)
- 4.3 Americas Neurological Drugs Sales Growth
- 4.4 APAC Neurological Drugs Sales Growth
- 4.5 Europe Neurological Drugs Sales Growth
- 4.6 Middle East & Africa Neurological Drugs Sales Growth
- 5 Americas
- 5.1 Americas Neurological Drugs Sales by Country
- 5.1.1 Americas Neurological Drugs Sales by Country (2019-2024)
- 5.1.2 Americas Neurological Drugs Revenue by Country (2019-2024)
- 5.2 Americas Neurological Drugs Sales by Type
- 5.3 Americas Neurological Drugs Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
- 6 APAC
- 6.1 APAC Neurological Drugs Sales by Region
- 6.1.1 APAC Neurological Drugs Sales by Region (2019-2024)
- 6.1.2 APAC Neurological Drugs Revenue by Region (2019-2024)
- 6.2 APAC Neurological Drugs Sales by Type
- 6.3 APAC Neurological Drugs Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan
- 7 Europe
- 7.1 Europe Neurological Drugs by Country
- 7.1.1 Europe Neurological Drugs Sales by Country (2019-2024)
- 7.1.2 Europe Neurological Drugs Revenue by Country (2019-2024)
- 7.2 Europe Neurological Drugs Sales by Type
- 7.3 Europe Neurological Drugs Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
- 8 Middle East & Africa
- 8.1 Middle East & Africa Neurological Drugs by Country
- 8.1.1 Middle East & Africa Neurological Drugs Sales by Country (2019-2024)
- 8.1.2 Middle East & Africa Neurological Drugs Revenue by Country (2019-2024)
- 8.2 Middle East & Africa Neurological Drugs Sales by Type
- 8.3 Middle East & Africa Neurological Drugs Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
- 9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
- 10 Manufacturing Cost Structure Analysis
- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Neurological Drugs
- 10.3 Manufacturing Process Analysis of Neurological Drugs
- 10.4 Industry Chain Structure of Neurological Drugs
- 11 Marketing, Distributors and Customer
- 11.1 Sales Channel
- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Neurological Drugs Distributors
- 11.3 Neurological Drugs Customer
- 12 World Forecast Review for Neurological Drugs by Geographic Region
- 12.1 Global Neurological Drugs Market Size Forecast by Region
- 12.1.1 Global Neurological Drugs Forecast by Region (2025-2030)
- 12.1.2 Global Neurological Drugs Annual Revenue Forecast by Region (2025-2030)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Neurological Drugs Forecast by Type
- 12.7 Global Neurological Drugs Forecast by Application
- 13 Key Players Analysis
- 13.1 Pfizer
- 13.1.1 Pfizer Company Information
- 13.1.2 Pfizer Neurological Drugs Product Portfolios and Specifications
- 13.1.3 Pfizer Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.1.4 Pfizer Main Business Overview
- 13.1.5 Pfizer Latest Developments
- 13.2 Ely Lilly
- 13.2.1 Ely Lilly Company Information
- 13.2.2 Ely Lilly Neurological Drugs Product Portfolios and Specifications
- 13.2.3 Ely Lilly Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.2.4 Ely Lilly Main Business Overview
- 13.2.5 Ely Lilly Latest Developments
- 13.3 Actavis
- 13.3.1 Actavis Company Information
- 13.3.2 Actavis Neurological Drugs Product Portfolios and Specifications
- 13.3.3 Actavis Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.3.4 Actavis Main Business Overview
- 13.3.5 Actavis Latest Developments
- 13.4 Mylan
- 13.4.1 Mylan Company Information
- 13.4.2 Mylan Neurological Drugs Product Portfolios and Specifications
- 13.4.3 Mylan Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.4.4 Mylan Main Business Overview
- 13.4.5 Mylan Latest Developments
- 13.5 Randox
- 13.5.1 Randox Company Information
- 13.5.2 Randox Neurological Drugs Product Portfolios and Specifications
- 13.5.3 Randox Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.5.4 Randox Main Business Overview
- 13.5.5 Randox Latest Developments
- 13.6 Intellipharmaceutics
- 13.6.1 Intellipharmaceutics Company Information
- 13.6.2 Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
- 13.6.3 Intellipharmaceutics Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.6.4 Intellipharmaceutics Main Business Overview
- 13.6.5 Intellipharmaceutics Latest Developments
- 13.7 Astrazeneca
- 13.7.1 Astrazeneca Company Information
- 13.7.2 Astrazeneca Neurological Drugs Product Portfolios and Specifications
- 13.7.3 Astrazeneca Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.7.4 Astrazeneca Main Business Overview
- 13.7.5 Astrazeneca Latest Developments
- 13.8 Lundbeck
- 13.8.1 Lundbeck Company Information
- 13.8.2 Lundbeck Neurological Drugs Product Portfolios and Specifications
- 13.8.3 Lundbeck Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.8.4 Lundbeck Main Business Overview
- 13.8.5 Lundbeck Latest Developments
- 13.9 Allergan
- 13.9.1 Allergan Company Information
- 13.9.2 Allergan Neurological Drugs Product Portfolios and Specifications
- 13.9.3 Allergan Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.9.4 Allergan Main Business Overview
- 13.9.5 Allergan Latest Developments
- 13.10 GSK
- 13.10.1 GSK Company Information
- 13.10.2 GSK Neurological Drugs Product Portfolios and Specifications
- 13.10.3 GSK Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.10.4 GSK Main Business Overview
- 13.10.5 GSK Latest Developments
- 13.11 Otsuka Pharmaceutical
- 13.11.1 Otsuka Pharmaceutical Company Information
- 13.11.2 Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
- 13.11.3 Otsuka Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.11.4 Otsuka Pharmaceutical Main Business Overview
- 13.11.5 Otsuka Pharmaceutical Latest Developments
- 13.12 Takeda
- 13.12.1 Takeda Company Information
- 13.12.2 Takeda Neurological Drugs Product Portfolios and Specifications
- 13.12.3 Takeda Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.12.4 Takeda Main Business Overview
- 13.12.5 Takeda Latest Developments
- 13.13 NHU Group
- 13.13.1 NHU Group Company Information
- 13.13.2 NHU Group Neurological Drugs Product Portfolios and Specifications
- 13.13.3 NHU Group Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.13.4 NHU Group Main Business Overview
- 13.13.5 NHU Group Latest Developments
- 13.14 Shionogi
- 13.14.1 Shionogi Company Information
- 13.14.2 Shionogi Neurological Drugs Product Portfolios and Specifications
- 13.14.3 Shionogi Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.14.4 Shionogi Main Business Overview
- 13.14.5 Shionogi Latest Developments
- 13.15 APOTEX
- 13.15.1 APOTEX Company Information
- 13.15.2 APOTEX Neurological Drugs Product Portfolios and Specifications
- 13.15.3 APOTEX Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.15.4 APOTEX Main Business Overview
- 13.15.5 APOTEX Latest Developments
- 13.16 North China Pharmaceutical
- 13.16.1 North China Pharmaceutical Company Information
- 13.16.2 North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
- 13.16.3 North China Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.16.4 North China Pharmaceutical Main Business Overview
- 13.16.5 North China Pharmaceutical Latest Developments
- 13.17 Harbin Pharmaceutical Co., Ltd.
- 13.17.1 Harbin Pharmaceutical Co., Ltd. Company Information
- 13.17.2 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
- 13.17.3 Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.17.4 Harbin Pharmaceutical Co., Ltd. Main Business Overview
- 13.17.5 Harbin Pharmaceutical Co., Ltd. Latest Developments
- 13.18 Lukang Pharmaceutical
- 13.18.1 Lukang Pharmaceutical Company Information
- 13.18.2 Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
- 13.18.3 Lukang Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.18.4 Lukang Pharmaceutical Main Business Overview
- 13.18.5 Lukang Pharmaceutical Latest Developments
- 13.19 Kelun Pharmaceutical
- 13.19.1 Kelun Pharmaceutical Company Information
- 13.19.2 Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
- 13.19.3 Kelun Pharmaceutical Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.19.4 Kelun Pharmaceutical Main Business Overview
- 13.19.5 Kelun Pharmaceutical Latest Developments
- 13.20 Kehua Biology
- 13.20.1 Kehua Biology Company Information
- 13.20.2 Kehua Biology Neurological Drugs Product Portfolios and Specifications
- 13.20.3 Kehua Biology Neurological Drugs Sales, Revenue, Price and Gross Margin (2019-2024)
- 13.20.4 Kehua Biology Main Business Overview
- 13.20.5 Kehua Biology Latest Developments
- 14 Research Findings and Conclusion
Table 1. Neurological Drugs Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Neurological Drugs Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Non-prescription drugs
Table 4. Major Players of Prescription
Table 5. Global Neurological Drugs Sales by Type (2019-2024) & (K Units)
Table 6. Global Neurological Drugs Sales Market Share by Type (2019-2024)
Table 7. Global Neurological Drugs Revenue by Type (2019-2024) & ($ million)
Table 8. Global Neurological Drugs Revenue Market Share by Type (2019-2024)
Table 9. Global Neurological Drugs Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Neurological Drugs Sales by Application (2019-2024) & (K Units)
Table 11. Global Neurological Drugs Sales Market Share by Application (2019-2024)
Table 12. Global Neurological Drugs Revenue by Application (2019-2024)
Table 13. Global Neurological Drugs Revenue Market Share by Application (2019-2024)
Table 14. Global Neurological Drugs Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Neurological Drugs Sales by Company (2019-2024) & (K Units)
Table 16. Global Neurological Drugs Sales Market Share by Company (2019-2024)
Table 17. Global Neurological Drugs Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Neurological Drugs Revenue Market Share by Company (2019-2024)
Table 19. Global Neurological Drugs Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Neurological Drugs Producing Area Distribution and Sales Area
Table 21. Players Neurological Drugs Products Offered
Table 22. Neurological Drugs Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Neurological Drugs Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Neurological Drugs Sales Market Share Geographic Region (2019-2024)
Table 27. Global Neurological Drugs Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Neurological Drugs Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Neurological Drugs Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Neurological Drugs Sales Market Share by Country/Region (2019-2024)
Table 31. Global Neurological Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Neurological Drugs Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Neurological Drugs Sales by Country (2019-2024) & (K Units)
Table 34. Americas Neurological Drugs Sales Market Share by Country (2019-2024)
Table 35. Americas Neurological Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Neurological Drugs Revenue Market Share by Country (2019-2024)
Table 37. Americas Neurological Drugs Sales by Type (2019-2024) & (K Units)
Table 38. Americas Neurological Drugs Sales by Application (2019-2024) & (K Units)
Table 39. APAC Neurological Drugs Sales by Region (2019-2024) & (K Units)
Table 40. APAC Neurological Drugs Sales Market Share by Region (2019-2024)
Table 41. APAC Neurological Drugs Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Neurological Drugs Revenue Market Share by Region (2019-2024)
Table 43. APAC Neurological Drugs Sales by Type (2019-2024) & (K Units)
Table 44. APAC Neurological Drugs Sales by Application (2019-2024) & (K Units)
Table 45. Europe Neurological Drugs Sales by Country (2019-2024) & (K Units)
Table 46. Europe Neurological Drugs Sales Market Share by Country (2019-2024)
Table 47. Europe Neurological Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Neurological Drugs Revenue Market Share by Country (2019-2024)
Table 49. Europe Neurological Drugs Sales by Type (2019-2024) & (K Units)
Table 50. Europe Neurological Drugs Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Neurological Drugs Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Neurological Drugs Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Neurological Drugs Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Neurological Drugs Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Neurological Drugs Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Neurological Drugs Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Neurological Drugs
Table 58. Key Market Challenges & Risks of Neurological Drugs
Table 59. Key Industry Trends of Neurological Drugs
Table 60. Neurological Drugs Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Neurological Drugs Distributors List
Table 63. Neurological Drugs Customer List
Table 64. Global Neurological Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Neurological Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Neurological Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Neurological Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Neurological Drugs Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Neurological Drugs Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Neurological Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Neurological Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Neurological Drugs Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Neurological Drugs Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Neurological Drugs Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Neurological Drugs Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Neurological Drugs Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Neurological Drugs Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Pfizer Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 79. Pfizer Neurological Drugs Product Portfolios and Specifications
Table 80. Pfizer Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. Pfizer Main Business
Table 82. Pfizer Latest Developments
Table 83. Ely Lilly Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 84. Ely Lilly Neurological Drugs Product Portfolios and Specifications
Table 85. Ely Lilly Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. Ely Lilly Main Business
Table 87. Ely Lilly Latest Developments
Table 88. Actavis Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 89. Actavis Neurological Drugs Product Portfolios and Specifications
Table 90. Actavis Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Actavis Main Business
Table 92. Actavis Latest Developments
Table 93. Mylan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 94. Mylan Neurological Drugs Product Portfolios and Specifications
Table 95. Mylan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Mylan Main Business
Table 97. Mylan Latest Developments
Table 98. Randox Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 99. Randox Neurological Drugs Product Portfolios and Specifications
Table 100. Randox Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Randox Main Business
Table 102. Randox Latest Developments
Table 103. Intellipharmaceutics Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 104. Intellipharmaceutics Neurological Drugs Product Portfolios and Specifications
Table 105. Intellipharmaceutics Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. Intellipharmaceutics Main Business
Table 107. Intellipharmaceutics Latest Developments
Table 108. Astrazeneca Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. Astrazeneca Neurological Drugs Product Portfolios and Specifications
Table 110. Astrazeneca Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Astrazeneca Main Business
Table 112. Astrazeneca Latest Developments
Table 113. Lundbeck Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 114. Lundbeck Neurological Drugs Product Portfolios and Specifications
Table 115. Lundbeck Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Lundbeck Main Business
Table 117. Lundbeck Latest Developments
Table 118. Allergan Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 119. Allergan Neurological Drugs Product Portfolios and Specifications
Table 120. Allergan Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. Allergan Main Business
Table 122. Allergan Latest Developments
Table 123. GSK Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 124. GSK Neurological Drugs Product Portfolios and Specifications
Table 125. GSK Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. GSK Main Business
Table 127. GSK Latest Developments
Table 128. Otsuka Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 129. Otsuka Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 130. Otsuka Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Otsuka Pharmaceutical Main Business
Table 132. Otsuka Pharmaceutical Latest Developments
Table 133. Takeda Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 134. Takeda Neurological Drugs Product Portfolios and Specifications
Table 135. Takeda Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. Takeda Main Business
Table 137. Takeda Latest Developments
Table 138. NHU Group Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 139. NHU Group Neurological Drugs Product Portfolios and Specifications
Table 140. NHU Group Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 141. NHU Group Main Business
Table 142. NHU Group Latest Developments
Table 143. Shionogi Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 144. Shionogi Neurological Drugs Product Portfolios and Specifications
Table 145. Shionogi Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 146. Shionogi Main Business
Table 147. Shionogi Latest Developments
Table 148. APOTEX Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 149. APOTEX Neurological Drugs Product Portfolios and Specifications
Table 150. APOTEX Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 151. APOTEX Main Business
Table 152. APOTEX Latest Developments
Table 153. North China Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 154. North China Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 155. North China Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 156. North China Pharmaceutical Main Business
Table 157. North China Pharmaceutical Latest Developments
Table 158. Harbin Pharmaceutical Co., Ltd. Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 159. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Product Portfolios and Specifications
Table 160. Harbin Pharmaceutical Co., Ltd. Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 161. Harbin Pharmaceutical Co., Ltd. Main Business
Table 162. Harbin Pharmaceutical Co., Ltd. Latest Developments
Table 163. Lukang Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 164. Lukang Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 165. Lukang Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 166. Lukang Pharmaceutical Main Business
Table 167. Lukang Pharmaceutical Latest Developments
Table 168. Kelun Pharmaceutical Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 169. Kelun Pharmaceutical Neurological Drugs Product Portfolios and Specifications
Table 170. Kelun Pharmaceutical Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 171. Kelun Pharmaceutical Main Business
Table 172. Kelun Pharmaceutical Latest Developments
Table 173. Kehua Biology Basic Information, Neurological Drugs Manufacturing Base, Sales Area and Its Competitors
Table 174. Kehua Biology Neurological Drugs Product Portfolios and Specifications
Table 175. Kehua Biology Neurological Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 176. Kehua Biology Main Business
Table 177. Kehua Biology Latest Developments
List of
Figure 1. Picture of Neurological Drugs
Figure 2. Neurological Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neurological Drugs Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Neurological Drugs Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Neurological Drugs Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Non-prescription drugs
Figure 10. Product Picture of Prescription
Figure 11. Global Neurological Drugs Sales Market Share by Type in 2023
Figure 12. Global Neurological Drugs Revenue Market Share by Type (2019-2024)
Figure 13. Neurological Drugs Consumed in Hospital
Figure 14. Global Neurological Drugs Market: Hospital (2019-2024) & (K Units)
Figure 15. Neurological Drugs Consumed in Clinic
Figure 16. Global Neurological Drugs Market: Clinic (2019-2024) & (K Units)
Figure 17. Global Neurological Drugs Sales Market Share by Application (2023)
Figure 18. Global Neurological Drugs Revenue Market Share by Application in 2023
Figure 19. Neurological Drugs Sales Market by Company in 2023 (K Units)
Figure 20. Global Neurological Drugs Sales Market Share by Company in 2023
Figure 21. Neurological Drugs Revenue Market by Company in 2023 ($ Million)
Figure 22. Global Neurological Drugs Revenue Market Share by Company in 2023
Figure 23. Global Neurological Drugs Sales Market Share by Geographic Region (2019-2024)
Figure 24. Global Neurological Drugs Revenue Market Share by Geographic Region in 2023
Figure 25. Americas Neurological Drugs Sales 2019-2024 (K Units)
Figure 26. Americas Neurological Drugs Revenue 2019-2024 ($ Millions)
Figure 27. APAC Neurological Drugs Sales 2019-2024 (K Units)
Figure 28. APAC Neurological Drugs Revenue 2019-2024 ($ Millions)
Figure 29. Europe Neurological Drugs Sales 2019-2024 (K Units)
Figure 30. Europe Neurological Drugs Revenue 2019-2024 ($ Millions)
Figure 31. Middle East & Africa Neurological Drugs Sales 2019-2024 (K Units)
Figure 32. Middle East & Africa Neurological Drugs Revenue 2019-2024 ($ Millions)
Figure 33. Americas Neurological Drugs Sales Market Share by Country in 2023
Figure 34. Americas Neurological Drugs Revenue Market Share by Country in 2023
Figure 35. Americas Neurological Drugs Sales Market Share by Type (2019-2024)
Figure 36. Americas Neurological Drugs Sales Market Share by Application (2019-2024)
Figure 37. United States Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 38. Canada Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 39. Mexico Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 40. Brazil Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 41. APAC Neurological Drugs Sales Market Share by Region in 2023
Figure 42. APAC Neurological Drugs Revenue Market Share by Regions in 2023
Figure 43. APAC Neurological Drugs Sales Market Share by Type (2019-2024)
Figure 44. APAC Neurological Drugs Sales Market Share by Application (2019-2024)
Figure 45. China Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 46. Japan Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 47. South Korea Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 48. Southeast Asia Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 49. India Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 50. Australia Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 51. China Taiwan Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 52. Europe Neurological Drugs Sales Market Share by Country in 2023
Figure 53. Europe Neurological Drugs Revenue Market Share by Country in 2023
Figure 54. Europe Neurological Drugs Sales Market Share by Type (2019-2024)
Figure 55. Europe Neurological Drugs Sales Market Share by Application (2019-2024)
Figure 56. Germany Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 57. France Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 58. UK Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 59. Italy Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 60. Russia Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 61. Middle East & Africa Neurological Drugs Sales Market Share by Country in 2023
Figure 62. Middle East & Africa Neurological Drugs Revenue Market Share by Country in 2023
Figure 63. Middle East & Africa Neurological Drugs Sales Market Share by Type (2019-2024)
Figure 64. Middle East & Africa Neurological Drugs Sales Market Share by Application (2019-2024)
Figure 65. Egypt Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 66. South Africa Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 67. Israel Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 68. Turkey Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 69. GCC Country Neurological Drugs Revenue Growth 2019-2024 ($ Millions)
Figure 70. Manufacturing Cost Structure Analysis of Neurological Drugs in 2023
Figure 71. Manufacturing Process Analysis of Neurological Drugs
Figure 72. Industry Chain Structure of Neurological Drugs
Figure 73. Channels of Distribution
Figure 74. Global Neurological Drugs Sales Market Forecast by Region (2025-2030)
Figure 75. Global Neurological Drugs Revenue Market Share Forecast by Region (2025-2030)
Figure 76. Global Neurological Drugs Sales Market Share Forecast by Type (2025-2030)
Figure 77. Global Neurological Drugs Revenue Market Share Forecast by Type (2025-2030)
Figure 78. Global Neurological Drugs Sales Market Share Forecast by Application (2025-2030)
Figure 79. Global Neurological Drugs Revenue Market Share Forecast by Application (2025-2030)
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Trusted Partners
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (09 May, 2026)
- Notify To Team (09 May, 2026)
- Report updation (10 May, 2026)
- Report Quality Check (10 May, 2026)
- Report Dispatch (11 May, 2026)
- Hard Copy
Recently Viewed Products
Global Neurological Drugs Market Growth 2024-2030
We are friendly and approachable, give us a call.